Funding to evaluate the potential of psilocybin to ease end-of-life distress.
Exploring the companies and themes that make up this emerging and exciting new sector
Numinus Announces Short Form Prospectus Offering of Units for Gross Proceeds of Up To $4.05 Million
Numinus is pricing its financing at CAD$0.27 per unit, with warrants priced at CAD$0.40.
Are Psychedelics The Answer For Addiction?
Globally, over 1 billion people are substance abusers. The U.S. addiction treatment market is already a $35 billion per year industry. Psychedelic drugs may be the (better) answer.
PharmaDrug Inc. Repays Amounts Owing Under Bridge Loan and Advisory Agreement, Completes Previously Announced Debt Restructuring and Provides Financial Update
Pharmadrug has completed a financial restructuring including retiring ~CAD$1.5 million in debt.
Why Getting In Early Is Especially Important With Psychedelics Stocks
The time is ripe for entry into psychedelics stocks.
Psychedelic Drugs and Seniors Health
Seniors are now the fastest-growing demographic of cannabis consumers. This same pattern may play out as psychedelic drugs are legalized and commercialized.
Red Light Holland Engages Radixmotion to Develop an Innovative Virtual Reality Shopping Experience for Dutch Smart Shops and e-Commerce Platforms
Red Light Holland is adding an education-based VR tool to its e-commerce platform.
Mydecine Innovations Group Inc. Announces NeuroPharm Inc. Commences PTSD Clinical Trial Initiative With Leading European Research Institute
Mydecine's recent acquisition, NeuroPharm Inc, is about to commence clinical trials using psilocybin to treat PTSD.
PharmaDrug Inc. Proposes a Strategic Mutual Investment with Red Light Holland Corp.
PharmaDrug (CAN:BUZZ / US:LMLLF) and Red Light Holland (CAN:TRIP) have entered into a share exchange agreement.
Why Psychedelics Microdosing Applications Have The Inside Track On Commercialization
Microdose-based psychedelic drug therapies have several advantages , ranging from R&D and drug licensing all the way through to drug commercialization and market penetration. It all adds up to greater profit potential.
Novamind Announces Closing of Oversubscribed Private Placement
NovaMind closes on a CAD$4.4 million financing, upsized from the original CAD$3.0 million placement.
Mydecine Innovations Group Inc. Signs Definitive Agreement for Acquisition of NeuroPharm Inc
This release confirms Mydecine's June 10th announcement of the acquisition of NeuroPharm Inc.